Abstract 84P
Background
Tumor-specific neoantigens arising from non-synonymous mutations have become increasingly attractive targets for immunotherapies. The accurate identification and prioritization of neoantigens is crucial to design personalized therapies for each cancer patient. Putative immunogenic neoantigens are currently selected by using several peptide-HLA-I binding predictors. While HLA-I binding affinity is essential to tumor cell presentation of neoantigens, it is insufficient to determine neoantigen immunogenicity. As such, the vast majority of predicted tumor neoantigens (98%) are not immunogenic and ineffective in activating antitumor responses. To address this challenge, we propose integrating T-cell receptor (TCR) repertoire profiles of tumor infiltrating lymphocytes (TILs), a key determinant of immunogenicity, in the current neoantigen prediction workflow.
Methods
We sequenced the CDR3 regions of TCR beta chain (TCRB) repertoire in 27 colorectal cancer (CRC) patients and predicted neopeptide-TCR binding by using our previously published predictor, epiTCR and another existing tool pMTNet. We constructed a machine learning model which considers both peptide-HLA-I and peptide-TCR binding features to prioritize high quality immunogenic neoantigen candidates. We further performed ELISpot assay on autologous PBMCs from four CRC patients to experimentally validate the effectiveness of our model. Finally, we selected the highest immunogenic candidate to perform 10X single-cell sequencing to identify the potential neoantigen-specific TCRs for cell-based vaccine development.
Results
We showed that 5.5% of neopeptide candidates despite having weak HLA-I binding affinity are capable of binding to TCR at predicted rank < 2%. The integrated model achieved higher accuracy for ranking immunogenic neopeptides than the conventional NetMHCpan tool solely relying on peptide-HLA-I binding features.
Conclusions
Our study presents an efficient process to select and prioritize neoantigens exhibiting both HLA presentation and immunogenicity for personalized cancer immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Genetics Institute.
Funding
Nexcalibur Therapeutics.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
613P - Differences in the interactions with pharmaceutical companies between medical oncologists and infectious diseases physicians
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
614P - The role of PD-L1 expression in prognosis of osteosarcoma patients: A systematic review and meta-analysis
Presenter: Alexander Purnomo
Session: Poster Display
Resources:
Abstract
615P - Pulmonary resectable metastases of osteosarcoma with apatinib and chemotherapy (PROACH): An open-label, single-arm phase II clinical trial
Presenter: Qiyuan Bao
Session: Poster Display
Resources:
Abstract
616P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Presenter: Paula Franco
Session: Poster Display
Resources:
Abstract
617P - The risk of acute myeloid leukaemia in patients with Ewing's sarcoma and trend analysis: A SEER-based study 2000-2020
Presenter: Mohamed Abdalla
Session: Poster Display
Resources:
Abstract
618P - Adult renal Ewing’s sarcoma/primitive neuroectodermal tumor: A 20-year retrospective review of molecular histopathological profiles, and clinical outcomes
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
619P - Single-cell and bulk RNA-seq analyses decode the renal microenvironment induced by polystyrene microplastics in mice receiving high-fat diet
Presenter: Wangrui Liu
Session: Poster Display
Resources:
Abstract
620P - A unique circulating microRNA pairs signature serves as a superior tool for early diagnosis of pan-cancer
Presenter: Dongyu Li
Session: Poster Display
Resources:
Abstract
621P - Effective identification of primary liver cancer from cirrhosis or chronic hepatitis virus infection using eight methylated plasma DNA markers: Marker discovery, phase I pilot, and phase II clinical validation
Presenter: Tian Yang
Session: Poster Display
Resources:
Abstract
622P - A prognostic and immune infiltration analysis of CCL26 in pan-cancer
Presenter: Mengyue Li
Session: Poster Display
Resources:
Abstract